Generic GLP-1 oral launch risk
Generic semaglutide expected to launch in India by March 2026; management believes GLP-1 orals serve weight management segment while insulin addresses insulinization, but delayed initiation is possible
SANOFI / Q2-FY26 / risks
Keep the risk register visible.
Sanofi India · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Export revenue volatility
Zentiva divestment impact on exports will continue affecting top line; while bottom line impact is limited, revenue volatility may persist
Partnership portfolio growth uncertainty
Analyst questioned why partnership growth at 2% appears subdued; management acknowledged competitive market and noted full partnership benefits not visible in reported numbers due to stock movements
High new product launch failure rate
Management acknowledged that >50% of new launches by Indian companies fail; company is selective about launching only products with strong value proposition and reimbursement support